ADAM17 promotes the malignant progression of ovarian cancer and causes chemo-resistance by mediating ADAM17-dependent shedding of AREG, HB-EGF, IL-6Rα, TNF, TNFR1-α, TGFα and activating the EGFR signaling pathway (198, 200). Here, TNF is linked to ovarian carcinoma.